Companies researching Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.
37
companies
List of companies that research Ocrevus (ocrelizumab)
This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

Employees14kRevenue$2.3BHigher Education
Ocrevus (ocrelizumab)Low confidence
Employees51Revenue$2MHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees107kRevenue$68BBiotechnology Research
Ocrevus (ocrelizumab)Low confidence
Employees730Hospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees193kRevenue$105BHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees1kHospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees127Business Consulting and Services
Ocrevus (ocrelizumab)Low confidence
Employees5Medical Practices
Ocrevus (ocrelizumab)Low confidence
Employees210Hospitals and Health Care
Ocrevus (ocrelizumab)Low confidence
Employees21kRevenue$26BBiotechnology Research
Ocrevus (ocrelizumab)Low confidence
Showing top companies out of 37 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.
Frequently asked questions